Stimulator Implant for Stroke Recovery
Trial Summary
What is the purpose of this trial?
This trial is testing a small implanted device that helps stroke survivors walk better by sending electrical signals to their muscles. The device is surgically placed and helps the muscles contract, making it easier to walk. This method has been shown to improve walking ability in stroke patients.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What data supports the effectiveness of the treatment IRS-8, Implanted Stimulator for Walking After Stroke, IRS-8, IST 12 & IST 16, IST 12 & IST 16, Brain-Computer Interface (BCI) Implant, Neurostimulation Device for stroke recovery?
Research shows that brain-computer interfaces (BCIs) can improve movement in stroke patients by strengthening brain connections, leading to better walking speed and motor function. Additionally, combining BCIs with functional electrical stimulation (FES) has been shown to enhance brain activation and motor control in stroke recovery.12345
Is the Stimulator Implant for Stroke Recovery generally safe for humans?
There is no specific safety data available for the Stimulator Implant for Stroke Recovery under the names provided. However, a systematic review on non-invasive electrical brain stimulation in stroke patients found that while there is potential for therapeutic benefits, comprehensive evaluation of adverse events is lacking.25678
How is the Stimulator Implant for Stroke Recovery treatment different from other stroke recovery treatments?
The Stimulator Implant for Stroke Recovery is unique because it combines a brain-computer interface (BCI) with a neurostimulation device to directly interact with the brain's sensory-motor system, potentially improving motor function after a stroke. This approach is different from traditional therapies as it aims to reintegrate the brain's control over movement, which is not typically addressed by conventional treatments.910111213
Research Team
Nathan Makowski, PhD
Principal Investigator
MetroHealth System, Ohio
Eligibility Criteria
This trial is for stroke survivors aged 21-75 who walk slower than normal due to the stroke. They should be at least 6 months post-stroke, have certain levels of muscle stiffness and motor function, and not need more than one person's help to walk. Participants must also be neurologically stable, speak English, not pregnant, without severe cognitive issues or medical conditions that increase fall risk.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Implantation, Controller Development, and Evaluation
Participants undergo surgery to implant a stimulator and electrodes, followed by training to use the device for walking assistance. Advanced controllers for walking are developed and evaluated over several months.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with evaluations at 18 and 44 weeks post-implant.
Treatment Details
Interventions
- IRS-8
- IST 12 & IST 16
IRS-8 is already approved in United States for the following indications:
- Improving walking in stroke survivors
Find a Clinic Near You
Who Is Running the Clinical Trial?
MetroHealth Medical Center
Lead Sponsor
Cleveland State University
Collaborator
Case Western Reserve University
Collaborator
Louis Stokes VA Medical Center
Collaborator